Importantly, the intrinsic CD71-binding ability of HFn facilitated tumor-specific targeting, enabling the nanocarrier to efficiently cross the blood–brain barrier (BBB) and accumulate in tumor tissues. The gene discussed is TFRC; the disease is neoplasm.